AcTION: A phase 1 study of [225Ac]Ac-PSMA-617 in men with PSMA-positive prostate cancer with or without prior [177Lu]Lu-PSMA-617 radioligand therapy
Lutetium (177Lu) vipivotide tetraxetan ([177Lu]Lu-PSMA-617;177Lu-PSMA-617) plus standard of care (SoC) significantlyprolongs radiographic progression-free survival (rPFS) and overall survival relative to best SoC alone in patients with prostate-specificmembrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). The AcTION study will assess the novel PSMA-targeted radioligand [225Ac]Ac-PSMA-617 (225Ac-PSMA-617), which delivers PSMA-guided 225Ac, a high‐energy α‐emitter able to createDNA double-strand breaks.
SATHEKGE Mike;
CRUMBAKER M;
JOSHUA A. M.;
BRUCHERTSEIFER Frank;
KREISL T;
EMINENI S;
WEHBE J;
KORN M;
MORGENSTERN Alfred;
EMMETT L;
2023-10-25
SPRINGER
JRC134428
1619-7070 (online),
https://link.springer.com/article/10.1007/s00259-023-06333-x,
https://publications.jrc.ec.europa.eu/repository/handle/JRC134428,
10.1007/s00259-023-06333-x (online),
Additional supporting files
| File name | Description | File type | |
|---|
